Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Centessa Pharmaceuticals plc | Chief Accounting Officer | Ordinary Shares | 53.1K | $423K | $7.96 | Mar 21, 2022 | Direct |
Vallon Pharmaceuticals, Inc. | Director | Common Stock | 9.51K | $38.8K | $4.08 | Dec 13, 2022 | Direct |
Evelo Biosciences, Inc. | Chief Financial Officer | Common Stock | 22.3K | $7.35K | $0.33 | Nov 8, 2023 | Direct |
Seres Therapeutics, Inc. | EVP and Chief Financial Officer | Stock Options (right to buy) | 700K | Mar 25, 2024 | Direct | ||
ESSA Pharma Inc. | Director | Options | 50K | Mar 25, 2024 | Direct | ||
Carisma Therapeutics Inc. | Director | Stock Option (Right to Buy) | 38.7K | Jul 1, 2024 | Direct | ||
Evelo Biosciences, Inc. | Chief Financial Officer | Restricted Stock Units | 6.5K | Nov 7, 2023 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
CARM | Carisma Therapeutics Inc. | Jul 1, 2024 | 1 | $0 | 4 | Jul 1, 2024 | Director |
CARM | Carisma Therapeutics Inc. | Jun 30, 2024 | 0 | $0 | 3 | Jul 1, 2024 | Director |
EPIX | ESSA Pharma Inc. | Mar 25, 2024 | 1 | $0 | 4 | Mar 28, 2024 | Director |
MCRB | Seres Therapeutics, Inc. | Mar 25, 2024 | 1 | $0 | 4 | Mar 27, 2024 | EVP and Chief Financial Officer |
MCRB | Seres Therapeutics, Inc. | Mar 25, 2024 | 0 | $0 | 3 | Mar 27, 2024 | EVP and Chief Financial Officer; Exhibit List: Exhibit 24 - Power of Attorney |
EVLO | Evelo Biosciences, Inc. | Nov 7, 2023 | 3 | -$598 | 4 | Nov 8, 2023 | Chief Financial Officer |
EVLO | Evelo Biosciences, Inc. | Nov 1, 2023 | 3 | -$1.32K | 4 | Nov 3, 2023 | Chief Financial Officer |
EVLO | Evelo Biosciences, Inc. | Sep 11, 2023 | 1 | $0 | 4 | Sep 13, 2023 | Chief Financial Officer |
EVLO | Evelo Biosciences, Inc. | Aug 7, 2023 | 3 | -$19.1K | 4 | Aug 9, 2023 | Chief Financial Officer |
EVLO | Evelo Biosciences, Inc. | May 8, 2023 | 1 | -$4.84K | 4 | May 10, 2023 | Chief Financial Officer |
EVLO | Evelo Biosciences, Inc. | May 7, 2023 | 2 | $0 | 4 | May 9, 2023 | Chief Financial Officer |
EVLO | Evelo Biosciences, Inc. | Feb 7, 2023 | 1 | $0 | 4 | Feb 9, 2023 | Chief Financial Officer |
GRI | Vallon Pharmaceuticals, Inc. | Dec 13, 2022 | 1 | $0 | 4 | Dec 15, 2022 | Director |
EVLO | Evelo Biosciences, Inc. | Sep 1, 2022 | 1 | $0 | 4 | Sep 1, 2022 | Chief Financial Officer |
EVLO | Evelo Biosciences, Inc. | Jul 13, 2022 | 0 | $0 | 3 | Jul 18, 2022 | Chief Financial Officer |
GRI | Vallon Pharmaceuticals, Inc. | Jul 1, 2022 | 1 | $0 | 4 | Jul 6, 2022 | Director |
EPIX | ESSA Pharma Inc. | Jun 29, 2022 | 1 | $0 | 4 | Nov 1, 2022 | Director |
GRI | Vallon Pharmaceuticals, Inc. | Jun 9, 2022 | 1 | $0 | 4 | Jun 10, 2022 | Director |
CNTA | Centessa Pharmaceuticals plc | Mar 21, 2022 | 1 | $0 | 4 | Mar 23, 2022 | Chief Accounting Officer |
CNTA | Centessa Pharmaceuticals plc | Feb 1, 2022 | 1 | $0 | 4 | Feb 3, 2022 | Chief Accounting Officer |
CNTA | Centessa Pharmaceuticals plc | Jun 2, 2021 | 1 | $20K | 4 | Jun 4, 2021 | Chief Accounting Officer |
CNTA | Centessa Pharmaceuticals plc | May 27, 2021 | 4 | $0 | 4 | Jun 1, 2021 | Chief Accounting Officer |
CNTA | Centessa Pharmaceuticals plc | May 27, 2021 | 0 | $0 | 3 | May 27, 2021 | Chief Accounting Officer |